Ronald Mitsuyasu, MD Ronald Mitsuyasu, MD Professor of Medicine Professor of Medicine Director, UCLA Center for Director, UCLA Center for Clinical AIDS Research and Clinical AIDS Research and Education Education Group Chairman, Group Chairman, AIDS Malignancy Consortium AIDS Malignancy Consortium (AMC) (AMC) Cancers in HIV: Cancers in HIV: A Growing Problem A Growing Problem
41
Embed
Ronald Mitsuyasu, MD Professor of Medicine Director, UCLA Center for Clinical AIDS Research and Education Group Chairman, AIDS Malignancy Consortium (AMC)
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Ronald Mitsuyasu, MDRonald Mitsuyasu, MD
Professor of MedicineProfessor of Medicine
Director, UCLA Center for Clinical Director, UCLA Center for Clinical AIDS Research and EducationAIDS Research and Education
Group Chairman,Group Chairman,AIDS Malignancy Consortium (AMC)AIDS Malignancy Consortium (AMC)
Cancers in HIV:Cancers in HIV:A Growing ProblemA Growing Problem
Number of people living with AIDS, AIDS-defining cancers, non-AIDS-defining cancers, and all cancers in the USA during 1991–2005.
Shiels M S et al. J Natl Cancer Inst 2011;103:753-762
Cancer Incidences in HIV in USA
Categorizing Cancers in PWHACategorizing Cancers in PWHA
• AIDS Defining CancerAIDS Defining Cancer
(decreasing)(decreasing)– KSKS
– NHL (BL, CNS, DLCBL)NHL (BL, CNS, DLCBL)
– Cervical Cancer ( added in Cervical Cancer ( added in 1993)1993)
• Non AIDS defining Non AIDS defining Cancers (increasing)Cancers (increasing)
– Anal CancerAnal Cancer
– Lung CancerLung Cancer
– Hodgkin LymphomaHodgkin Lymphoma
– Liver CancerLiver Cancer
• Elevated risk but rareElevated risk but rare
– Merkel CarcinomaMerkel Carcinoma
– LeiomyosarcomaLeiomyosarcoma
– Salivary gland LECSalivary gland LEC
• Unchanged riskUnchanged risk
– BreastBreast
– ColorectalColorectal
– ProstateProstate
– Follicular lymphomaFollicular lymphoma
Cancer is the One of the Most Frequent Causes of Cancer is the One of the Most Frequent Causes of Death in HIV-Infected PatientsDeath in HIV-Infected Patients
Cause of DeathCause of Death 20002000 20052005
Cancer (all)Cancer (all) 29%29% 34%34%
Cancer - AIDS definingCancer - AIDS defining 16%16% 13%13%
Cancer - Non-AIDS definingCancer - Non-AIDS defining 13%13% 21%21%
• HIV may activate cellular genes or proto-oncogenes or HIV may activate cellular genes or proto-oncogenes or inhibit tumor suppressor genesinhibit tumor suppressor genes
• HIV induces genetic instability (e.g 6 fold higher number of HIV induces genetic instability (e.g 6 fold higher number of MA in HIV lung CA over non-HIV)MA in HIV lung CA over non-HIV)11
• Increase susceptibility to effects of carcinogens Increase susceptibility to effects of carcinogens
• Endothelial/epithelial cell abnormalities induced or Endothelial/epithelial cell abnormalities induced or facilitated by HIV may allow for cancer developmentfacilitated by HIV may allow for cancer development
• Population differences based on genetics and exposure to Population differences based on genetics and exposure to carcinogens carcinogens
Wistuba Il, Pathogenesis of NADC: a review. AIDS Pt Care 1999;13:415-26Wistuba Il, Pathogenesis of NADC: a review. AIDS Pt Care 1999;13:415-26
Outcomes of cancer in HIVOutcomes of cancer in HIV
• With prolonged survival of HIV population and aging, more people With prolonged survival of HIV population and aging, more people will develop cancer, especially NADCs.will develop cancer, especially NADCs.
• HIV-infected cancer patients may have worse outcomes in some HIV-infected cancer patients may have worse outcomes in some cancerscancers
– Late presentation, advanced stageLate presentation, advanced stage
– Poor access to carePoor access to care
– Medical comorbidity, treatment toxicityMedical comorbidity, treatment toxicity
• Unclear if HIV has adverse impact on cancer behavior, immune Unclear if HIV has adverse impact on cancer behavior, immune control, cancer-free survivalcontrol, cancer-free survival
• Limited data for guiding cancer treatment in HIV-infected people Limited data for guiding cancer treatment in HIV-infected people
Biggar Biggar JAIDS JAIDS 2005, Little 2005, Little J Clin Oncol J Clin Oncol 2008, Rengan 2008, Rengan Lancet Oncol Lancet Oncol 2012, Suneja 2012, Suneja AIDS AIDS 20132013
Anogenital CancersAnogenital Cancers
Anogenital CancersAnogenital Cancers
• Invasive cervical carcinomaInvasive cervical carcinoma– Considered an AIDS-defining conditionConsidered an AIDS-defining condition
– Leading cause of cancer death in women worldwideLeading cause of cancer death in women worldwide
• Anal cancerAnal cancer11
– Not AIDS defining but very common and growing incidenceNot AIDS defining but very common and growing incidence
• Oral and Head/Neck cancer also HPV relatedOral and Head/Neck cancer also HPV related
• HPV involvementHPV involvement1-21-2
– Both derive from precancerous lesions due to HPVBoth derive from precancerous lesions due to HPV
– Most cancer causing strains: 16, 18, 31, 33, 35, 45Most cancer causing strains: 16, 18, 31, 33, 35, 45
– Repeated infections and infection with multiple HPV strains Repeated infections and infection with multiple HPV strains increase the risk of developing neoplasia increase the risk of developing neoplasia
– Cancer can be prevented with early diagnosis and vaccinesCancer can be prevented with early diagnosis and vaccines1Phelps RM, et al. Int J Cancer. 2001;94:753-757.2Martin F, et al. Sex Transm Infect. 2001;77:327-331.
Spectrum of HPV diseaseSpectrum of HPV disease
Morphologic Continuum
Low-grade disease High-grade disease
Rectalmucosa
Columns ofMorgagni
Dentate(pectinate)
line
Squamousmucosa
Skin
Levator animuscle
Subcutaneous
DeepExternalsphincter ani
muscles Superficial
Anal anatomyAnal anatomy
Ryan DP et al. New Engl J Med. 2000;342:792-800.
Anal and Cervical Cancer IncidenceAnal and Cervical Cancer IncidenceAnal and Cervical Cancer IncidenceAnal and Cervical Cancer Incidence
Cervical cancer prior to cervical cytology Cervical cancer prior to cervical cytology screening in general pop: 40-50/100,000screening in general pop: 40-50/100,000
Cervical cancer currently: 8-10/100,000Cervical cancer currently: 8-10/100,000 Anal cancer among HIV+ MSM in USA: Anal cancer among HIV+ MSM in USA:
up to 137/100,000up to 137/100,000
American Cancer Society. Cervical cancer facts. 2006.Daling JR et al. N Engl J Med. 1987;317:973-977.
Chin-Hong PU, Palefsky JM. Dermatol Ther. 2005;18:67-76.
19
Prevalence of anal HPV detection among MSMPrevalence of anal HPV detection among MSMPopulation-based dataPopulation-based data
Chin-Hong et al. Ann Int Med. 2008;149;300-6.
57
88
6672
34
46
0
20
40
60
80
100HPVHPV-HR
Pre
vale
nce
, %
HIV-seropositiveparticipants
HIV-negativeparticipants
All participants
Redfield IRC 2100Redfield IRC 2100
LymphomasLymphomas
Pathology of AIDS-RelatedPathology of AIDS-RelatedNon-Hodgkin’s LymphomaNon-Hodgkin’s Lymphoma
• Small noncleaved-cell lymphomaSmall noncleaved-cell lymphoma
– Burkitt’s lymphoma and Burkitt-like lymphoma Burkitt’s lymphoma and Burkitt-like lymphoma
– Large noncleaved-cell lymphomaLarge noncleaved-cell lymphoma
– CD30+ anaplastic large B-cell lymphomaCD30+ anaplastic large B-cell lymphoma
• Plasmablastic lymphoma Plasmablastic lymphoma
• Advanced stage (>75% III or IV)Advanced stage (>75% III or IV)
• Extranodal involvement Extranodal involvement
– Central nervous system, liver, bone marrow, gastrointestinalCentral nervous system, liver, bone marrow, gastrointestinalTirelli U, et al. AIDS. 2000;14:1675-1688.
EBV-positive tumors
Burkitt’s lymphoma Nasopharyngeal carcinoma
AIDS-related Lymphoma Experience Suggests AIDS-related Lymphoma Experience Suggests Cancer Treatment Outcome Can be Equivalent Cancer Treatment Outcome Can be Equivalent
to General Populationto General Population
0
50
100
0 6 12 18 24 36 48
Months
Pe
rce
nt
Su
rviv
al
NCI EPOCH CD4 > 99
NCI EPOCH
1997-1998: HAART Era
1991-1994: Pre-HAART
NCI DLBCL non-AIDS
Besson et al. Blood. 2001; 98: 2339-2344Little et al Blood. 2003; 101: 4653-4659
Hodgkin’s DiseaseHodgkin’s Disease
• Association with HIV-infectionAssociation with HIV-infection
– Hodgkin’s disease: RR: 5 to 30Hodgkin’s disease: RR: 5 to 30
– Non-Hodgkin’s disease: RR: 24 to 165Non-Hodgkin’s disease: RR: 24 to 165
– Incidence increasing rapidly in post HAART eraIncidence increasing rapidly in post HAART era
– >95% are EBV+>95% are EBV+
• Patients with HIV present with:Patients with HIV present with:
– B symptoms (70% to 96%), worse histology, higher-stage B symptoms (70% to 96%), worse histology, higher-stage tumor (74% to 92% are III or IV), bone marrow involvement tumor (74% to 92% are III or IV), bone marrow involvement (40% to 50%), pancytopenia(40% to 50%), pancytopenia
• Good response to MOPP/ABVGood response to MOPP/ABV
– 2-year disease-free survival: 62% but more relapses in HIV2-year disease-free survival: 62% but more relapses in HIV
– Early good results with Stanford V, BEACOPP and Early good results with Stanford V, BEACOPP and brentuximab vendotinbrentuximab vendotin
Gerard L, et al. AIDS. 2003;17:81-87.
Kaposi’s SarcomaKaposi’s Sarcoma
Kaposi’s SarcomaKaposi’s Sarcoma
• One of the first recognized AIDS-defining illnessesOne of the first recognized AIDS-defining illnesses
• Vascular tumor that may involve mucocutaneous, lymphatic, Vascular tumor that may involve mucocutaneous, lymphatic, gastrointestinal, and pulmonary sitesgastrointestinal, and pulmonary sites
– Human herpesvirus-8 (HHV8) or KSHVHuman herpesvirus-8 (HHV8) or KSHV
• HHV8 HHV8
– DNA virus found in both HIV+ and HIV- KS. DNA virus found in both HIV+ and HIV- KS.
– Tropism for B cells and endothelial cells, high titers in salivaTropism for B cells and endothelial cells, high titers in saliva
– Also associated with primary effusion lymphoma, Castleman’s Also associated with primary effusion lymphoma, Castleman’s disease, and angioimmunoblastic lymphadenopathy in HIV disease, and angioimmunoblastic lymphadenopathy in HIV
– Genome codes for viral homologs of human proteins involved in Genome codes for viral homologs of human proteins involved in cell cycle regulation and signalingcell cycle regulation and signaling
• HIV- and Kaposi’s sarcoma-induced angiogenic and HIV- and Kaposi’s sarcoma-induced angiogenic and inflammatory cytokines also stimulate Kaposi’s sarcoma cell inflammatory cytokines also stimulate Kaposi’s sarcoma cell growthgrowth
• TransmissionTransmission• Mostly MSM in USMostly MSM in US• IVDU and Heterosexual as wellIVDU and Heterosexual as well
• Resource limited setting – Africa and S. AmericaResource limited setting – Africa and S. America• KS still most common cancer in HIVKS still most common cancer in HIV
• PrevalencePrevalence• 1300 cases/100,000 persons/yr 1992 1300 cases/100,000 persons/yr 1992 • 170 cases/100,000 persons/yr 2006170 cases/100,000 persons/yr 2006• Decline of 10% / yearDecline of 10% / year• Cause of considerable morbidity and mortality in Cause of considerable morbidity and mortality in
Africa and Latin AmericaAfrica and Latin America
Clinical ManifestationsClinical Manifestations
• Mucocutaneous, macular or nodular, dark colorMucocutaneous, macular or nodular, dark color
• As patients live longer with HIV, morbidity and As patients live longer with HIV, morbidity and mortality from cancers are increasingmortality from cancers are increasing
• The types of cancers in HIV may vary in different The types of cancers in HIV may vary in different populations around the worldpopulations around the world
• Treatment of malignancies in HIV should be vigorous Treatment of malignancies in HIV should be vigorous and appropriate to the situationand appropriate to the situation
• Side effects of therapy should be treated/preventedSide effects of therapy should be treated/prevented
• Prevention strategies for virally-associated Prevention strategies for virally-associated malignancies in HIV need to be investigatedmalignancies in HIV need to be investigated
• Through prospective clinical trials research can Through prospective clinical trials research can treatment and prevention strategies be effectively treatment and prevention strategies be effectively evaluatedevaluated
Thank YouThank You
• For information on AMC clinical trials see:For information on AMC clinical trials see:http://www.aidscancer.orghttp://www.aidscancer.org
• For information on NCI programs in HIV For information on NCI programs in HIV cancer see:cancer see:
• To refer for AMC clinical trials in LA, call To refer for AMC clinical trials in LA, call UCLA CARE Center UCLA CARE Center 310-557-1891 310-557-1891 ask for ask for Maricela Gonzalez or page/email Dr. Maricela Gonzalez or page/email Dr. Mitsuyasu, Mitsuyasu, [email protected]@mednet.ucla.edu